Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Income (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Net Income for 15 consecutive years, with $62000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Net Income rose 105.0% to $62000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $116000.0, a 108.7% increase, with the full-year FY2025 number at $620000.0, up 118.65% from a year prior.
  • Net Income was $62000.0 for Q2 2025 at Aytu Biopharma, up from $54000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $381000.0 in Q3 2024 to a low of -$53.1 million in Q1 2022.
  • A 5-year average of -$8.7 million and a median of -$1.2 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: crashed 546.8% in 2021, then surged 158.89% in 2024.
  • Aytu Biopharma's Net Income stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then surged by 87.46% to -$839000.0 in 2023, then soared by 114.66% to $123000.0 in 2024, then plummeted by 49.59% to $62000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Income are $62000.0 (Q2 2025), $54000.0 (Q1 2025), and $123000.0 (Q4 2024).